Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Inflammation inhibition
October 2016
SHARING OPTIONS:

HALLE (SAALE), Germany—Biopharmaceutical company Probiodrug AG recently shared the latest results of its glutaminyl cyclase (QC) inhibitor in an inflammation animal model, specifically a mouse model of thioglycollate-induced peritonitis. PQ912 was found to inhibit monocyte infiltration, increase eosinophils (a type of white blood cell) and enhance resolvin D2, a lipid mediator that contributes to terminating inflammatory processes. These data were generated together with Ambiotis SAS.
 
“The development of therapeutics that act agonistically on resolutive pathways is a new emerging approach to correctly terminate inflammation and fight chronic status. We are very glad that our research team was able to bring first evidence on the potential of QC inhibitors as pro-resolutive compounds. Results for PQ912 are thus very promising for the field, showing that resolution pharmacology opens an avenue for treatments that act on the endogenous capacity of the body to stop inflammation,” said Dr. Marc Dubourdeau, CEO and chief scientific officer of Ambiotis.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.